A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients

被引:36
作者
Dumont, A. G. [1 ]
Rink, L. [2 ]
Godwin, A. K. [2 ,3 ]
Miettinen, M. [4 ]
Joensuu, H. [5 ]
Strosberg, J. R. [6 ]
Gronchi, A. [7 ]
Corless, C. L. [8 ,9 ]
Goldstein, D. [10 ]
Rubin, B. P. [11 ,12 ]
Maki, R. G. [13 ]
Lazar, A. J. [14 ]
Lev, D. [15 ]
Trent, J. C. [1 ]
von Mehren, M. [2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA
[2] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
[3] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Lawrence, KS 66045 USA
[4] Armed Forces Inst Pathol, Dept Soft Tissue Pathol, Washington, DC 20306 USA
[5] Univ Helsinki, Cent Hosp, Dept Oncol, Helsinki, Finland
[6] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Gastrointestinal Oncol, Tampa, FL 33682 USA
[7] Natl Tumor Inst, Dept Surg, Milan, Italy
[8] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA
[9] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[10] Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia
[11] Lerner Res Inst, Dept Mol Genet, Cleveland, OH USA
[12] Cleveland Clin, Taussig Canc Ctr, Dept Anat Pathol, Cleveland, OH 44106 USA
[13] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[14] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[15] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
关键词
beta-catenin; deep fibromatosis; desmoid tumor; GIST; imatinib; KIT; BETA-CATENIN GENE; SYNCHRONOUS OCCURRENCE; INTERSTITIAL-CELLS; IMATINIB MESYLATE; KIT MUTATIONS; DOSE IMATINIB; PHASE-II; C-KIT; SURVIVAL; SARCOMA;
D O I
10.1093/annonc/mdr442
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gastrointestinal stromal tumors (GISTs) and desmoid tumors (DTs) are two rare mesenchymal tumor. Anecdotal reports of individuals with both diseases led us to make the hypothesis that the association is a nonrandom event as the probability would be extremely low to observe such cases if they were independent events. We evaluated the existence of patients with GIST and DT in a large multicenter cohort at 10 institutions in the United States, Australia and Europe. Data on gender, age at diagnosis, KIT, PDGFRA, CTNNB1 mutation status and follow-up time after diagnosis were collected. We identified 28 patients diagnosed with both tumors. DT was diagnosed after GIST in 75% of patients and concomitantly in 21%. In only one case (4%), GIST was diagnosed after DT. KIT or PDGFRA mutations were detected in 12 of 14 GIST, 9 in KIT exon 11, 2 in KIT exon 9 and 1 in PDGFRA. A statistical analysis of these 28 cases suggests a nonrandom association between GIST and DT. Further studies may be able to elucidate the underlying biology responsible for this association.
引用
收藏
页码:1335 / 1340
页数:6
相关论文
共 47 条
[1]   Gastrointestinal stromal tumours in patients with other-type cancer: A mere coincidence or an etiological association? - A study of 97 GIST cases [J].
Agaimy, A ;
Wuensch, PH .
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2005, 43 (09) :1025-1030
[2]   Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors [J].
Agaram, Narasimhan P. ;
Wong, Grace C. ;
Guo, Tianhua ;
Maki, Robert G. ;
Singer, Samuel ;
DeMatteo, Ronald P. ;
Besmer, Peter ;
Antonescu, Cristina R. .
GENES CHROMOSOMES & CANCER, 2008, 47 (10) :853-859
[3]   Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT [J].
Blanke, Charles D. ;
Demetri, George D. ;
von Mehren, Margaret ;
Heinrich, Michael C. ;
Eisenberg, Burton ;
Fletcher, Jonathan A. ;
Corless, Christopher L. ;
Fletcher, Christopher D. M. ;
Roberts, Peter J. ;
Heinz, Daniela ;
Wehre, Elisabeth ;
Nikolova, Zariana ;
Joensuu, Heikki .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :620-625
[4]   TRIAD OF GASTRIC LEIOMYOSARCOMA, FUNCTIONING EXTRA-ADRENAL PARAGANGLIOMA AND PULMONARY CHONDROMA [J].
CARNEY, JA ;
SHEPS, SG ;
GO, VLW ;
GORDON, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1977, 296 (26) :1517-1518
[5]   Desmoids in familial adenomatous polyposis [J].
Clark, SK ;
Phillips, RKS .
BRITISH JOURNAL OF SURGERY, 1996, 83 (11) :1494-1504
[6]   Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group [J].
Debiec-Rychter, M ;
Dumez, H ;
Judson, I ;
Wasag, B ;
Verweij, J ;
Brown, M ;
Dimitrijevic, S ;
Sciot, R ;
Stul, M ;
Vranck, H ;
Scurr, M ;
Hagemeijer, A ;
Van Glabbeke, M ;
van Oosterom, AT .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (05) :689-695
[7]   KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours [J].
Debiec-Rychter, Maria ;
Sciot, Raf ;
Le Cesne, Axel ;
Schlemmer, Marcus ;
Hohenberger, Peter ;
van Oosterom, Allan T. ;
Blay, Jean-Yves ;
Leyvraz, Serge ;
Stul, Michel ;
Casali, Paolo G. ;
Zalcberg, John ;
Verweij, Jaap ;
Van Glabbeke, Martine ;
Hagemeijer, Anne ;
Judson, Ian .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (08) :1093-1103
[8]   Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].
Demetri, GD ;
von Mehren, M ;
Blanke, CD ;
Van den Abbeele, AD ;
Eisenberg, B ;
Roberts, PJ ;
Heinrich, MC ;
Tuveson, DA ;
Singer, S ;
Janicek, M ;
Fletcher, JA ;
Silverman, SG ;
Silberman, SL ;
Capdeville, R ;
Kiese, B ;
Peng, B ;
Dimitrijevic, S ;
Druker, BJ ;
Corless, C ;
Fletcher, CDM ;
Joensuu, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480
[9]   Paraneoplastic insulin resistance syndrome in advanced aggressive fibromatosis (Desmoid tumor) treated by imatinib mesylate [J].
Folli, Franco ;
Galimberti, Gabriella ;
Pastore, Matteo ;
Davalli, Alberto M. .
DIABETES CARE, 2006, 29 (09) :2178-2180
[10]   Occurrence of other tumors in patients with GIST [J].
Goncalves, Rinaldo ;
Linhares, Eduardo ;
Albagli, Rafael ;
Valadao, Marcus ;
Vilhena, Bruno ;
Romano, Sergio ;
Ferreira, Carlos Gil .
SURGICAL ONCOLOGY-OXFORD, 2010, 19 (04) :E140-E143